The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 11, 2019

Filed:

Dec. 07, 2017
Applicant:

Stemline Therapeutics, Inc, New York, NY (US);

Inventor:

Ivan Bergstein, New York, NY (US);

Assignee:

Stemline Therapeutics, Inc., New York, NY (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 15/86 (2006.01); C12N 5/10 (2006.01); C07K 16/28 (2006.01); C12N 9/10 (2006.01); A61K 39/00 (2006.01); C07K 16/18 (2006.01); C12N 5/16 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); C12N 9/1048 (2013.01); C12N 9/1077 (2013.01); C12N 15/86 (2013.01); C12Y 204/02036 (2013.01); A61K 39/00 (2013.01); C07K 16/18 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/55 (2013.01); C12N 5/163 (2013.01);
Abstract

The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3Rα. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3Rα chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3Rα-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3Rα.


Find Patent Forward Citations

Loading…